Integrative Analysis of CRC Liver Metastasis

NCT02917707 · tracked via the Priya Life Science China tracker

Sponsor

Da Fu

Phase

Observational

Started

2016-01

Last updated

2016-09-28

Condition(s) studied

Metastasis

Investigational drug(s) / intervention(s)

normal colorectal tissues

normal colorectal tissues: The investigators will extract total protein, DNA and RNA from these groups.

Study summary

The investigators will perform integrative analysis of CRC liver metastasis

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: * Age ≤ 75 years with histologically proven CRC * No severe major organ dysfunction * WHO performance status of 0 or 1 * No prior cancer chemotherapy Exclusion Criteria: * Age ≥ 76 * Severe major organ dysfunction * World Health Organization (WHO) performance status of \>1 * Prior cancer chemotherapy

Primary outcome measure(s)

5 years overall survival — 5 years

Trial sites (2)

Facility	City	Region	Status
Ganzhou City People's Hospital	Ganzhou	Jiangxi	Recruiting
Shanghai Tenth People's Hospital	Shanghai	Shanghai Municipality	Recruiting

Other trials for the same condition

Somatostatin Receptor PET/CT in SSTR-Related Disease Patients Recruiting

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC Recruiting

Chemokine Receptor 4 PET/CT Imaging of CXCR4-Related Diseases Recruiting

Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients Recruiting

A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02917707 on ClinicalTrials.gov ↗ ← All trials in China